ProCE Banner Activity

BIC/FTC/TAF Safe and Efficacious in Women and Girls Across 5 Phase II/III Clinical Trials

Slideset Download
Conference Coverage
In pooled analysis of 373 treatment-naive and virologically suppressed females, no emergent resistance or discontinuation for renal or bone adverse events was observed.

Released: November 20, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare